Australia’s Novotech added to its IT infrastructure investment by launching Oracle’s Trial Management and Monitoring Cloud Service (TMMCS) to support its work in the Asia-Pacific region.
It is the largest implementation of TMMCS in that region, and Novotech becomes the first biotech-focused CRO in Asia-Pacific to use the technology.
TMMCS provides a real-time look into clinical trial progress and significant utilization rates of clinic and staff resources that helps lower costs while increasing speed and data quality, the company said. The technology also ensures regulatory compliance, integration with global studies and gives clinic staff and clients better data visibility.
“Oracle’s cloud technology provides a centralized trial database enabling improved access, control and governance of clinical data,” John Moller, M.D., Novotech’s chief executive, said in a statement. “The system is highly configurable allowing us to tailor process flows and alerts to client needs, as well as ensuring effective control on deviation.”
The CRO, which has seen a very busy year with the additions of new partners and clinics, now has 10 strategic collaborations with hospitals and research institutions across the Asia-Pacific region.